Welcome to our dedicated page for Redhill Biopharm SEC filings (Ticker: RDHL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The RedHill Biopharma Ltd. (Nasdaq: RDHL) SEC filings page on Stock Titan provides centralized access to the company’s Form 20-F annual reports and Form 6-K current reports, which together document its regulatory, clinical, commercial and financing activities. As a foreign private issuer focused on gastrointestinal diseases, infectious diseases and oncology, RedHill uses Form 6-K extensively to furnish press releases and other information to the U.S. Securities and Exchange Commission.
In these filings, investors can review detailed disclosures about Talicia®, RedHill’s FDA-approved oral therapy for Helicobacter pylori infection in adults, including its indication, QIDP-based market exclusivity, patent coverage and ex-U.S. licensing arrangements. Filings also describe the company’s late-stage development programs: opaganib (ABC294640), a sphingosine kinase-2 selective inhibitor with anticancer, anti-inflammatory and antiviral activity; RHB-102 (Bekinda®), an extended-release ondansetron formulation for multiple gastrointestinal and oncology-support indications; RHB-204, an optimized formulation of RHB-104 for Crohn’s disease and pulmonary nontuberculous mycobacteria disease; and RHB-107 (upamostat), a host-directed serine protease inhibitor in late-stage development for non-hospitalized symptomatic COVID-19 and other conditions.
RedHill’s Form 6-K reports also cover capital markets and financing transactions, such as at-the-market offering programs, purchase agreements for American Depositary Shares, and amendments to ownership thresholds. Additional filings document Nasdaq listing compliance matters, including notifications related to the minimum stockholders’ equity requirement and subsequent confirmation of regained compliance, as well as legal proceedings like New York Supreme Court judgments and Korean court attachment orders in the Kukbo dispute.
Stock Titan’s interface is designed to surface these filings as they are furnished to EDGAR and to pair them with AI-powered summaries that explain the key points of lengthy documents. Users can quickly identify items such as quarterly and interim financial information, registration statement incorporations by reference, and governance or financing updates, while drilling down into full-text filings when more detail is needed.
RedHill Biopharma Ltd. director Tsimchi Ofer filed an initial Form 3 reporting his equity holdings in the company. The filing shows direct ownership of 146,250,000 Ordinary Shares and 3,644 American Depositary Shares (ADSs), which are convertible into Ordinary Shares at the holder’s election with no expiration date.
Ofer also reports 14,625 unvested restricted share units, each linked to one ADS and settled in Ordinary Shares. In addition, he holds stock options over 150,000, 90,000 and 180,000 Ordinary Shares, with exercise prices of $5,000, $4,870 and $7,080 per ADS, expiring on May 6, 2029, March 25, 2030 and April 28, 2031, respectively.
RedHill Biopharma Ltd. director and Chief Commercial Officer Rick D. Scruggs filed an initial Form 3 disclosing his holdings in the company. As of the filing, he directly owns 312,500,000 Ordinary Shares, along with American Depositary Shares (ADSs) and equity awards linked to additional Ordinary Shares.
His equity-based compensation includes 31,250 unvested restricted share units, each tied to one ADS and settled in Ordinary Shares, plus 7,364 ADSs that are convertible at any time with no expiration date. He also holds fully vested stock options covering 750,000, 300,000, 70,000 and 840,000 Ordinary Shares, each granted under the RedHill 2010 Option Plan with exercise prices per ADS of $6,840, $7,000, $7,000 and $6,620, expiring between February 25, 2029 and July 25, 2031.
RedHill Biopharma Ltd. director Reed Kenneth filed an initial ownership report showing equity interests in the company. He holds 10,520 unvested restricted share units, each tied to one American Depositary Share and settled in ordinary shares, plus 2,583 ADSs that are convertible at any time and have no expiration date.
He also holds stock options to purchase 90,000 ordinary shares (equivalent to 9 ADSs) at an exercise price of $4,870 per ADS expiring on March 25, 2030, 150,000 ordinary shares (equivalent to 15 ADSs) at $7,000 per ADS expiring on May 6, 2029, and 250,000 ordinary shares (equivalent to 25 ADSs) at $6,620 per ADS expiring on July 25, 2031. These options are fully vested and exercisable.
RedHill Biopharma’s Chief Operating Officer Raday Gilead has filed an initial Form 3 reporting his equity holdings. He holds 30,758 unvested restricted share units, each linked to one American Depositary Share (ADS), and 4,537 ADSs that are convertible at any time with no expiration date.
The filing also lists several stock option grants to purchase Ordinary Shares: 250,000 and 400,000 shares with an exercise price of $5,000 per ADS, 600,000 shares at $4,870 per ADS, and 570,000 and 180,000 shares at $7,080 per ADS. Most option grants are described as fully vested and exercisable, with expirations between March 2028 and April 2031.
RedHill Biopharma Ltd. director Mamluk Roni has filed an initial ownership report detailing existing equity awards and share holdings. The filing shows 10,350 unvested restricted share units, each tied to one American Depositary Share (ADS). Each ADS represents 10,000 ordinary shares of RedHill Biopharma Ltd.
The RSUs are subject to time-based vesting conditions and are settled in ordinary shares. The report also discloses 1,350 ADSs that are convertible at any time at the holder’s election and have no expiration date. This Form 3 does not reflect new buy or sell transactions, only current beneficial ownership.
RedHill Biopharma Ltd. Chief Financial Officer Ingber Razi filed a Form 3 reporting existing equity interests in the company, rather than new open‑market trades. The filing lists American Depositary Shares (ADSs), restricted share units (RSUs) and stock options tied to Ordinary Shares.
The holdings include 27,756 unvested RSUs, each for one ADS, with each ADS representing 10,000 Ordinary Shares of par value NIS 0.01. The filing also notes 6,691 ADSs that are convertible at any time with no expiration date, plus fully vested stock options to purchase 20,000, 30,000, 170,000 and 230,000 Ordinary Shares at fixed exercise prices per ADS, expiring between August 29, 2028 and April 28, 2031.
RedHill Biopharma Ltd. executive Guy Joel Goldberg filed a Form 3 reporting his initial ownership in the company. He directly holds American Depositary Shares and Ordinary Shares, including 30,572 unvested restricted share units, each tied to one ADS that represents 10,000 Ordinary Shares. He also holds fully vested stock options to purchase 250,000, 450,000, 370,000 and 600,000 Ordinary Shares at exercise prices of $5,000, $4,870, $5,000 and $7,080 per ADS, expiring between 2028 and 2031.
RedHill Biopharma executive Adi Frish filed an initial ownership report showing existing equity interests, not new trades. He reports 27,681 unvested restricted share units tied to American Depositary Shares, 6,280 ADSs that are convertible at any time, stock options over 250,000, 370,000, 600,000 and 750,000 ordinary shares, and 276,810,000 ordinary shares held directly.
RedHill Biopharma Ltd. director Cabilly Shmuel has filed an initial ownership report detailing a substantial equity stake in the company. He directly holds 105,200,000 Ordinary Shares, along with American Depositary Shares, restricted share units and stock options linked to additional Ordinary Shares.
The holdings include 10,520 unvested restricted share units, each tied to one American Depositary Share (ADS) that represents 10,000 Ordinary Shares, and 3,063 ADSs that are convertible at any time at the holder’s election and have no expiration date. He also holds fully vested stock options to purchase 90,000 Ordinary Shares at an exercise price of $4,870 per ADS expiring on March 25, 2030, and options to purchase 180,000 Ordinary Shares at an exercise price of $7,080 per ADS expiring on April 28, 2031.
RedHill Biopharma Ltd. director and Chief Executive Officer Dror Ben-Asher filed an initial ownership report showing substantial equity and option interests in the company. He directly holds 441,350,000 Ordinary Shares and 10,336 American Depositary Shares (ADSs)
The filing also discloses 44,135 unvested restricted share units (RSUs)750,000, 500,000, 900,000, and 1,100,000 Ordinary Shares at exercise prices of $5,000, $5,000, $4,870, and $7,080 per ADS, expiring between 2028 and 2031.